SITC Cancer Immunotherapy Guidelines (CIGs) are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients. These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. The Immune Checkpoint Inhibitor‐Related Adverse Events Expert Panel was developed to generate consensus statements focusing on toxicities associated with checkpoint inhibitors.
Julie R. Brahmer, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Marc S. Ernstoff, MD
Roswell Park Comprehensive Cancer Center